Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart Disease.

Gregory G Schwartz Lawrence Alan LeiterChristie M BallantynePhilip J BarterDonald M BlackDavid KallendFouzia Laghrissi-ThodeEran LeitersdorfJohn Joseph Valentine McMurrayStephen J NichollsAnders G OlssonDavid PreissPrediman K ShahJean-Claude TardifJohn Kittelson

Published in: Diabetes care (2020)

In patients with a recent acute coronary syndrome, incident diabetes is common and is reduced substantially by treatment with dalcetrapib.

Keyphrases